[EN] ISOINDOLONE COMPOUNDS AS HPK1 INHIBITORS<br/>[FR] COMPOSÉS D'ISOINDOLONE EN TANT QU'INHIBITEURS DE HPK1
申请人:PFIZER
公开号:WO2021224818A1
公开(公告)日:2021-11-11
This invention relates to compounds of general Formula I and pharmaceutically acceptable salts thereof, in which R1, R2, R2a, R3, R4, (R5)a and X are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
Synthesis of 5,10,15,20-Tetrakis(4-<i>tert</i>- butyl-2,6-dicarboxyphenyl)porphyrin: A Versatile Bis-Faced Porphyrin Synthon for <i>D</i><sub>4</sub>-Symmetric Chiral Porphyrins
[see structure]. A versatile bis-faced porphyrinsynthon, 5,10,15,20-tetrakis(4-tert-butyl-2,6-dicarboxyphenyl)porphyrin, was synthesized. The eight carboxyl groups were readily converted into various amide groups, and condensation with chiral amines led to various D4-symmetric chiral porphyrins with rigid structures.
Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them
申请人:RUDOLF Klaus
公开号:US20070208036A1
公开(公告)日:2007-09-06
The present invention relates to compounds of general formula
R-Z
1
-Z
2
-Z
3
-R (I),
wherein
R, R
1
and Z
1
to Z
3
are defined as in claim
1
, the tautomers, the diastereomers, the enantiomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable pharmacological properties, particularly CGRP-antagonistic properties, pharmaceutical compositions containing these compounds, their use and processes for preparing them.
[EN] HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME<br/>[FR] COMPOSÉ HÉTÉROCYCLIQUE ET DISPOSITIF ÉLECTROLUMINESCENT ORGANIQUE LE COMPRENANT<br/>[KO] 헤테로고리 화합물 및 이를 포함하는 유기 발광 소자
申请人:LG CHEMICAL LTD
公开号:WO2019164340A1
公开(公告)日:2019-08-29
본 명세서는 화학식 1의 헤테로고리 화합물 및 이를 포함하는 유기 발광 소자에 관한 것이다.